CN105477052A - Kushen gel for treating mixed vaginal diseases and application thereof - Google Patents
Kushen gel for treating mixed vaginal diseases and application thereof Download PDFInfo
- Publication number
- CN105477052A CN105477052A CN201410482098.9A CN201410482098A CN105477052A CN 105477052 A CN105477052 A CN 105477052A CN 201410482098 A CN201410482098 A CN 201410482098A CN 105477052 A CN105477052 A CN 105477052A
- Authority
- CN
- China
- Prior art keywords
- radix sophorae
- sophorae flavescentis
- gel
- parts
- metronidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a Kushen gel for treating mixed vaginal diseases and application thereof. Active ingredients of the Kushen gel are metronidazole and Radix Flavescentis extract. The Radix Flavescentis extract comprises oxymatrine. The clinical study on the Kushen gel has exact and evident effect for treating mixed vaginal diseases.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of Radix Sophorae Flavescentis gel and application thereof for the treatment of mixed type vagina.
Background technology
Vagina is commonly encountered diseases and the frequently-occurring disease of women, brings many miseries to patient, has a strong impact on the healthy of numerous women.Nitre imidazoles antimicrobial drug metronidazole has the effect of anaerobe resistant, anti-trichomonal, and triazole antifungal agent econazole nitrate and miconazole nitrate have antifungal effect.At present, metronidazole suppository, Metrogel etc. is had for the treatment of trichomonal vaginitis, bacterial vaginosis etc.; There is econazole nitrate bolt for the treatment of vaginal candidiasis, the double infection that Miconazole in Miconazole Suppository topical therapeutic vulvovaginal candidiasis and gram-positive bacteria cause; Have metronidazole, clotrimazole and chlorhexidine three the compound preparation metronidazole,clotrimazole and chlorhexidine acetate suppositories, metronidazole effervescence patch etc. of medicine coupling for bacterial vaginosis, mycotic vagina, anti-protozoal vagina, antibacterial mycete protozoon mixed infection vagina.We know, gynecological's common vaginal disease is trichomonas vagina, mycotic vagina, bacterial vaginosis clinically.Infusorian in mixed infection, mycete mixed infection are more common, and mycete, antibacterial superinfection are actually rare, and infusorian, mycete, antibacterial triple infection are then extremely rare especially.And bacterial vaginosis the main pathogenic fungi is anaerobe, the medicine of generally acknowledging both at home and abroad anaerobic infection is metronidazole.In vagina, dysbacteriosis is the common cause of disease simultaneously, and its key to recover the microflora environment of vagina, instead of all kill, anaerobe, aerobe, fungus etc. because can destroy microecological environment further on the contrary so simultaneously.Therefore, in the safe class preparation of two azoles, the basis of metronidazole, clotrimazole coupling adds a broad-spectrum bactericide disinfectant chlorhexidine there is no need.Chlorhexidine, in this not specific aim medication, may cause the generation of the side reactions such as dysbacteriosis on the contrary or increase the incidence rate of side reaction, even causing drug-induced disease.Therefore a kind of medicine that can improve treatment mixed type vagina effect how is provided to be those skilled in the art's technical problems urgently to be resolved hurrily.
Summary of the invention
The object of the present invention is to provide a kind of Radix Sophorae Flavescentis gel and application thereof for the treatment of mixed type vagina effect, in order to realize object of the present invention, intending adopting following technical scheme:
One aspect of the present invention relates to a kind of Radix Sophorae Flavescentis gel for the treatment of mixed type vagina, and the active component of Radix Sophorae Flavescentis gel is metronidazole and Radix Sophorae Flavescentis extract, and described Radix Sophorae Flavescentis extract comprises oxymatrine.
In a preferred embodiment of the present invention, described Radix Sophorae Flavescentis extract is oxymatrine.
In a preferred embodiment of the present invention, described metronidazole and the weight ratio of Radix Sophorae Flavescentis extract are 5-7:1, are preferably 6:1.
In a preferred embodiment of the present invention, the formula of the Radix Sophorae Flavescentis gel of described treatment mixed type vagina is oxymatrine 10 parts, metronidazole 60 parts, hyaluronic acid 20 parts, carbomer 94550 parts, glycerol 200 parts, triethanolamine 120 parts, deionized water add to 800 parts.
The present invention also relates to the application of Radix Sophorae Flavescentis gel in preparation treatment mixed type vagina medicine of above-mentioned treatment mixed type vagina on the other hand, and preferably, described metronidazole and oxymatrine are present in medicine with the dosage of synergistic function.
Wherein vagina comprises the inflammation such as vaginitis.
The Radix Sophorae Flavescentis gel for the treatment of mixed type vagina of the present invention by clinical research, treatment mixed type vagina determined curative effect, obviously.
Detailed description of the invention
If not specified, the conventional means that technological means used in embodiment is well known to those skilled in the art.
Embodiment 1:
1, case is collected
In October ,-2013 in October, 2012, be proved clinical patients 50 example infecting mixed type vagina.Separately establish 20 routine positive controls (diagnose identical, treat with Metrogel)
2, diagnostic criteria:
Western medicine diagnose standard: Main Basis histopathology is also diagnosed in conjunction with clinical observation, the sensations such as scorching hot, dry, pruritus and pain are had according to clinical symptoms vagina, secretions increases, vaginal mucosa has graininess pustule or little petechia, and secretions inspection is determined infected (mycete, infusorian, ameba etc.).
3, case inclusive criteria
(1) the 20-50 year sexual intercourse women of above diagnostic criteria is met;
(2) accept treatment voluntarily can pay a return visit, the person that completes clinical treatment observation on request on time;
(3) without other acute and chronic complication;
(4) antibiotics therapist is not accepted selected the first half;
(5) hepatic and renal function is normal without severe drug allergies person.
4, case exclusion standard
(1) trimester of pregnancy, women breast-feeding their children or find conceived person after entering group;
(2) enter the rear stopped treatment of group or require bolter;
(3) course for the treatment of is not completed or not in accordance with regulation medication person;
(4) treatments period is looked into and is suffered from the treatment of other diseases needs and may affect this research therapist;
5, research method
Treatment group: (oxymatrine 10 parts, metronidazole 60 parts, hyaluronic acid 20 parts, carbomer 94550 parts, glycerol 200 parts, triethanolamine 120 parts, deionized water add to 800 parts to Radix Sophorae Flavescentis gel, concrete technology flow process is: when rapid stirring, hyaluronic acid is added portions of de-ionized water lentamente, make it to dissolve completely, dissolve carbomer 945 with portions of de-ionized water; By the deionized water solution suction vacuum emulsification tank of oxymatrine and metronidazole, then residue deionized water, glycerol are added in vacuum emulsification tank, stir vacuumize degassing, add triethanolamine, evacuation, degassed to product bubble-free simultaneously, is cooled to room temperature.), medicine-feeding method: adopt aseptic povidone iodine cotton balls wiping to remove vaginal wall secretions and cervical mucus after having a bath before sleep, appropriate (about 10g) gel is pushed to vaginal orifice, and taking-up of getting up morning abandons, being used in conjunction 10 is a course for the treatment of, and menstrual phase is discontinued medication.Terminate clean period check indices one course for the treatment of.
Matched group: the Metrogel using oxygen-freeization matrine.
6, curative effect determinate standard
(1) clinical symptoms, sign efficacy assessment standard (with reference to scoring after National Drug Administration's " new Chinese medicine guideline of clinical investigations " improvement)
Recovery from illness: clinical symptoms, somatic feature score are than >=90%;
Effective: 70%≤clinical symptoms, somatic feature score are than < 90%;
Effective: 30%≤clinical symptoms, somatic feature score are than < 70;
Invalid: clinical symptoms, somatic feature score are than < 30;
Total mark × 100%. before integration ratio=(treat front total mark one and treat rear total mark)/treatment
7, clinical indices criterion
Recovery from illness: transference cure, secretions does not detect infection; Effective: transference cure, secretions detects Simple infection;
Effective: transference cure; Invalid: symptom does not disappear.
9, the results are shown in Table 1
Table 1 Clinical symptom and sign integration efficacy determination table
| Group | Number of cases | Recovery from illness | Effective | Effectively | Invalid | Cure rate |
| Treatment group | 50 | 32 | 12 | 5 | 1 | 64％ |
| Matched group | 20 | 6 | 5 | 4 | 5 | 30％ |
Known according to table 1, for patients symptomatic's sign, treatment group treatment total effective rate reaches 98%, cure rate 64%, and matched group effective percentage is 75%, cure rate is 30%, two groups are compared, and difference is extremely remarkable, and treatment group is obviously better than matched group (p < 0.01).Illustrate that oxymatrine and metronidazole have significant synergism on treatment mixed type vagina, can obviously improve patient clinical symptom and sign.
The above is the preferred embodiments of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from principle of the present invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (7)
1. treat a Radix Sophorae Flavescentis gel for mixed type vagina, it is characterized in that, the active component of Radix Sophorae Flavescentis gel is metronidazole and Radix Sophorae Flavescentis extract, and described Radix Sophorae Flavescentis extract comprises oxymatrine.
2. Radix Sophorae Flavescentis gel according to claim 1, is characterized in that, described Radix Sophorae Flavescentis extract is oxymatrine.
3. Radix Sophorae Flavescentis gel according to claim 1 and 2, is characterized in that, described metronidazole and the weight ratio of Radix Sophorae Flavescentis extract are 5-7:1.
4. Radix Sophorae Flavescentis gel according to claim 3, is characterized in that, described metronidazole and the weight ratio of Radix Sophorae Flavescentis extract are 6:1.
5. Radix Sophorae Flavescentis gel according to claim 1, it is characterized in that, the formula of the Radix Sophorae Flavescentis gel of described treatment mixed type vagina is oxymatrine 10 parts, metronidazole 60 parts, hyaluronic acid 20 parts, carbomer 94550 parts, glycerol 200 parts, triethanolamine 120 parts, deionized water add to 800 parts.
6. treat the application of Radix Sophorae Flavescentis gel in preparation treatment mixed type vagina medicine of mixed type vagina for one kind.
7. application according to claim 6, described metronidazole and oxymatrine are present in medicine with the dosage of synergistic function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410482098.9A CN105477052A (en) | 2014-09-19 | 2014-09-19 | Kushen gel for treating mixed vaginal diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410482098.9A CN105477052A (en) | 2014-09-19 | 2014-09-19 | Kushen gel for treating mixed vaginal diseases and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105477052A true CN105477052A (en) | 2016-04-13 |
Family
ID=55664567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410482098.9A Pending CN105477052A (en) | 2014-09-19 | 2014-09-19 | Kushen gel for treating mixed vaginal diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105477052A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729655A (en) * | 2016-11-18 | 2017-05-31 | 珠海市新辅仁药业有限公司 | A kind of bacteriostatic gel and preparation method thereof |
| CN111529568A (en) * | 2020-05-29 | 2020-08-14 | 贵阳新天药业股份有限公司 | Application of total matrines in preparation of medicine for treating vulva lichen sclerosus |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101276A (en) * | 1994-04-13 | 1995-04-12 | 吴晓景 | External-use medicine composition for vaginitis |
| CN1163123A (en) * | 1996-04-23 | 1997-10-29 | 吴一宾 | Mongolian medicine for curing venereal disease |
| CN1589848A (en) * | 2003-09-01 | 2005-03-09 | 深圳太太药业有限公司 | Anti inflammatory bacteria inhibiting medicinal composition and its preparation method |
| CN1969990A (en) * | 2006-08-09 | 2007-05-30 | 王爱民 | Preparation process of Chinese medicinal composition for treating gynecological disease and gel thereof |
| CN101837043A (en) * | 2009-12-03 | 2010-09-22 | 艾金长 | Medicament for curing gynaopathy |
| CN103385926A (en) * | 2013-07-09 | 2013-11-13 | 武汉烺祺生物科技有限公司 | Antibiosis gel for curing cervical and vaginal diseases of gynaecology |
-
2014
- 2014-09-19 CN CN201410482098.9A patent/CN105477052A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1101276A (en) * | 1994-04-13 | 1995-04-12 | 吴晓景 | External-use medicine composition for vaginitis |
| CN1163123A (en) * | 1996-04-23 | 1997-10-29 | 吴一宾 | Mongolian medicine for curing venereal disease |
| CN1589848A (en) * | 2003-09-01 | 2005-03-09 | 深圳太太药业有限公司 | Anti inflammatory bacteria inhibiting medicinal composition and its preparation method |
| CN1969990A (en) * | 2006-08-09 | 2007-05-30 | 王爱民 | Preparation process of Chinese medicinal composition for treating gynecological disease and gel thereof |
| CN101837043A (en) * | 2009-12-03 | 2010-09-22 | 艾金长 | Medicament for curing gynaopathy |
| CN103385926A (en) * | 2013-07-09 | 2013-11-13 | 武汉烺祺生物科技有限公司 | Antibiosis gel for curing cervical and vaginal diseases of gynaecology |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729655A (en) * | 2016-11-18 | 2017-05-31 | 珠海市新辅仁药业有限公司 | A kind of bacteriostatic gel and preparation method thereof |
| CN111529568A (en) * | 2020-05-29 | 2020-08-14 | 贵阳新天药业股份有限公司 | Application of total matrines in preparation of medicine for treating vulva lichen sclerosus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101829041B (en) | Sterilizing and itch-relieving gynaecological lotion | |
| CN103301502A (en) | Gynecological medical gel dressing and preparation method thereof | |
| CN101850047A (en) | Chinese medicinal composition for treating eczema and preparation thereof | |
| CN105477052A (en) | Kushen gel for treating mixed vaginal diseases and application thereof | |
| CN104771671A (en) | Traditional Chinese medicine lotion for treating gynecological inflammation | |
| CN103007126A (en) | Traditional Chinese medicine decoction for treating colpitis mycotica | |
| CN105343165A (en) | Polyhexamethylene guanidine propionate lotion, gel and suppository for department of gynecology | |
| CN109674945A (en) | The Chinese medicine composition and preparation method thereof of ulcer is cured in a kind of myogenic hemostasia and detumescence analgesic | |
| CN106943444A (en) | One kind treats dermopathic pharmaceutical composition and its production and use | |
| CN102641277B (en) | Ointment for treating gynaopathy and dermatoses and preparation method thereof | |
| CN105477010A (en) | Antibacterial nursing spray | |
| CN105362289A (en) | Vagina-retained boric acid preparation and preparation method thereof | |
| CN104189657B (en) | External contraceptive capable of preventing and curing genital tract infection | |
| Sobel | Antimicrobial resistance in vulvovaginitis | |
| CN102886029A (en) | Traditional Chinese medicine composition for treating endometritis of milk cow | |
| CN103127490A (en) | Medicinal composition for treating vulvovaginal candidiasis | |
| CN101618192A (en) | Pharmaceutical application of pharmaceutical composition containing zedoary turmeril oil | |
| CN107080817A (en) | A kind of Novel gynecology-department a thousand pieces of gold oil of zedoary turmeric bolt | |
| CN105560248A (en) | Pharmaceutical composition for treating fungal infection and preparing method and application thereof | |
| CN1289102C (en) | Chinese-western medicine compound suppository for treating prostatic diseases | |
| CN105853825A (en) | Traditional Chinese medicine composition gel for treating rheumatic arthritis and preparation method of traditional Chinese medicine composition gel | |
| CN105770448A (en) | Medicine composition for preventing and treating perianal diseases and preparation method thereof | |
| Wang et al. | Effect of diluted iodophor solution washing and external application of purple elm ointment combined with traditional Chinese medicine decoction washing on perineal incision of patients undergoing perineal lateral resection after delivery | |
| CN104606295A (en) | Non-antibiotic antifungal externally used medicine | |
| CN114452329A (en) | Medicine for treating mycotic vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160413 |
|
| RJ01 | Rejection of invention patent application after publication |